In head and neck cancer cells, a series of excellent studies from the Myers’ group have shown that cells expressing lower levels of p53 protein displayed reduced metabolic diversity, with an increased dependence on glucose which can form the basis for a therapeutic strategy [49]. This evidence concerns the gene TP53 and head and neck cancer.